ライフサイエンスコーパス: antifungal drug

1 s inhibited by ketoconazole, a commonly used antifungal drug.

2 on glucose utilization in the presence of an antifungal drug.

3 itraconazole, a triazole that is used as an antifungal drug.

4 in growth and virulence and as a target for antifungal drugs.

5 h species had high in vitro MICs to multiple antifungal drugs.

6 e presence of sterol biosynthesis-inhibiting antifungal drugs.

7 ubingensis isolates had low in vitro MICs to antifungal drugs.

8 ertain Archaea and is a potential target for antifungal drugs.

9 ant roles in cell growth and as a target for antifungal drugs.

10 fungal enzymes may provide a new target for antifungal drugs.

11 dulates cell cycle dynamics and responses to antifungal drugs.

12 l synthesis is a primary pathway targeted by antifungal drugs.

13 y high mortality despite the availability of antifungal drugs.

14 f C. glabrata to develop resistance to azole antifungal drugs.

15 tress, including the response to azole-class antifungal drugs.

16 ave many complex mechanisms of resistance to antifungal drugs.

17 genic fungi and promotes resistance to azole antifungal drugs.

18 athways commonly targeted by clinically used antifungal drugs.

19 therefore be targeted for the design of new antifungal drugs.

20 rate utilization by fungi in the presence of antifungal drugs.

21 ation of potential protein targets for novel antifungal drugs.

22 in its endemic regions, and discovery of new antifungal drugs.

23 hylogeny and corresponding susceptibility to antifungal drugs.

24 ncluding species innately resistant to azole antifungal drugs.

25 This step should be an effective target for antifungal drugs.

26 uced by echinocandins, a front-line class of antifungal drugs.

27 d according to CLSI document M38-A2 for nine antifungal drugs.

28 ltidrug transporter and hence sensitivity to antifungal drugs.

29 cells resistant to host defenses and certain antifungal drugs.

30 ion and may be targeted for developing novel antifungal drugs.

31 itro antifungal susceptibility against eight antifungal drugs.

32 fferent ways to detect potential targets for antifungal drugs.

33 ments have increased susceptibility to azole antifungal drugs.

34 H3 gene dosage affects resistance to polyene antifungal drugs.

35 MD) for the determination of MICs of various antifungal drugs.

36 Resistance to the antifungal drug 5-fluorocytosine was not deleterious and

37 tral role for calcineurin B in virulence and antifungal drug action in the human fungal pathogen C. n

38 and may potentiate both innate immunity and antifungal drug activity against A. fumigatus.

39 ge-scale studies of virulence mechanisms and antifungal drug activity in candidiasis.

40 ive conformation of PalH, which might act as antifungal drugs against ascomycetes.

41 ons between the immunosuppressive agents and antifungal drugs against many pathogenic fungi, includin

42 n vitro antifungal susceptibilities of eight antifungal drugs against the Ochroconis isolates reveale

43 resulted in increased susceptibility to the antifungal drug amphotericin B.

44 l meningitis relies on three old, off-patent antifungal drugs: amphotericin B deoxycholate, flucytosi

45 as increased sensitivity to a wide range of antifungal drugs and cell wall inhibitors, and impaired

46 riod, and efficacy with different classes of antifungal drugs and different yeast isolates.

47 state in which they are highly resistant to antifungal drugs and express the drug efflux determinant

48 s associated with identifying broad-spectrum antifungal drugs and highlight novel targets that could

49 d profound effects both on susceptibility to antifungal drugs and on the levels of secreted proteinas

50 , melanization, protease production, MICs of antifungal drugs, and growth rates in vitro.

51 uction, increased susceptibility to triazole antifungal drugs, and is avirulent in a murine model of

52 nterest as a potential target for developing antifungal drugs, and the genes encoding glucan and chit

53 Although there was a flurry of new antifungal drugs approved in the early part of the last

54 Only a few classes of antifungal drugs are available, so the emergence of resi

55 timely diagnosis and early intervention with antifungal drugs are key factors in the successful treat

56 n shown previously to give resistance to the antifungal drug aureobasidin A, leading us to predict th

57 wth defect when grown in the presence of the antifungal drug Brefeldin A (BFA), indicating that H3K4

58 tunicamycin, dithiothreitol, and azole-class antifungal drugs can induce nonapoptotic cell death in y

59 Limited antifungal drug choices and emergence of drug-resistant

60 The antifungal drug, clotrimazole, demonstrated ability to i

61 growth of cells in the presence of supra-MIC antifungal drug concentrations.

62 This long antifungal drug coordinates the P450 heme iron with the

63 ts because of toxicity and resistance to the antifungal drugs currently in use.

64 gal growth, and we currently pursue it as an antifungal drug design target.

65 l pathogens, and represent novel targets for antifungal drug design.

66 gi, HCS has been proposed as a candidate for antifungal drug design.

67 dating a URA3-disrupted gene as a target for antifungal drug development could be devised, it is clea

68 Antifungal drug development lags far behind in compariso

69 ntifungal agents will be of great use in the antifungal drug development process.

70 geting the calcineurin signaling cascade for antifungal drug development, we examined the activity of

71 tial utility of gene expression profiling in antifungal drug development.

72 sents an attractive target for antiprotozoal/antifungal drug development.

73 malian host and thus an excellent target for antifungal drug development.

74 important implications for pathogenesis and antifungal drug development.

75 dent processes at the host-pathogen axis for antifungal drug development.

76 nd there are a limited number of targets for antifungal drug development; as a result the antifungal

77 ngal pathogens and are promising targets for antifungal drug discovery because their domain compositi

78 ole carboxylase enzyme as a novel target for antifungal drug discovery is discussed.

79 nism, it represents an unexplored target for antifungal drug discovery.

80 inesin may offer promise as cidal agents for antifungal drug discovery.

81 for cell division, cell wall remodeling, and antifungal drug discovery.

82 This study suggests two new targets for antifungal drug discovery.

83 presents an ideal target for structure-based antifungal drug discovery.

84 both innate and acquired resistance against antifungal drugs, due to its ability to modify ergostero

85 nical breakpoints are available to delineate antifungal drug efficacy in non-Aspergillus invasive mol

86 is disease, as well as for the evaluation of antifungal drug efficacy.

87 oides develops spontaneous resistance to the antifungal drug FK506 (tacrolimus) via two distinct mech

88 h encodes the target of the immunosuppresive antifungal drugs FK506 and rapamycin.

89 n-3 polymer (poly-betaNM) is superior to the antifungal drug fluconazole for all three strains examin

90 combination of either CsA or FK506 with the antifungal drug fluconazole that perturbs synthesis of t

91 (5b, 6i) were fungicidal, unlike a standard antifungal drug fluconazole, which was fungistatic.

92 assessed by assays for sequestration of the antifungal drug fluconazole.

93 , and many compounds that synergize with the antifungal drug fluconazole.

94 ins of C. albicans that are resistant to the antifungal drugs fluconazole and amphotericin B.

95 oints for the most commonly prescribed azole antifungal drug, fluconazole, can be difficult to determ

96 WP1 is a promising target for development of antifungal drugs for treatment of oroesophageal candidia

97 pplicable to the determination MICs of other antifungal drugs for yeasts.

98 of membrane-embedded transporters to efflux antifungal drugs from the cells.

99 y of infection, and new diagnostic tests and antifungal drugs have become available.

100 Some antifungal drugs have been reformulated to reduce toxici

101 New classes of antifungal drugs have only been partly successful in imp

102 a novel class of drug, the orotomides, is an antifungal drug in clinical development that demonstrate

103 ding that thiabendazole, an orally available antifungal drug in clinical use for 40 years, also poten

104 The strategy of combining antifungal drugs in a treatment regimen may improve the

105 in Malawi, assessed the ability of different antifungal drugs in selective agar to reduce contaminati

106 Susceptibilities of the isolates to eight antifungal drugs in vitro showed mostly high MICs, excep

107 Additionally, antifungal drugs, including amphotericin B, liposomal am

108 ergosterol synthesis, and the azole class of antifungal drugs inhibits Erg11.

109 , a US Food and Drug Administration-approved antifungal drug, inhibits the Hedgehog (HH) signaling pa

110 esistance to the limited number of available antifungal drugs is a serious problem in the treatment o

111 ucomatous conditions, while voriconazole, an antifungal drug, is retinotoxic.

112 Using a sordarin derivative, an antifungal drug, it was possible to determine the struct

113 y hepatic stellate cells that identified the antifungal drug itraconazole (ITA) as an inhibitor of MF

114 elial cell proliferation identified the oral antifungal drug itraconazole as a novel agent with poten

115 photericin B (AmB) is an effective but toxic antifungal drug, known to increase the permeability of t

116 id assay may aid in the selection of initial antifungal drugs, leading to improved patient outcomes.

117 strains of Candida are becoming resistant to antifungal drugs, making the treatment of candidiasis di

118 peculate that this lengthy exposure to azole antifungal drugs may have caused or promoted the atypica

119 d not metabolize lanosterol, and the topical antifungal drug miconazole was the strongest inhibitor t

120 rturbations of cell wall biosynthesis by the antifungal drugs nikkomycin Z (a chitin synthase inhibit

121 evolving in parallel in the presence of the antifungal drug nystatin are frequently incompatible wit

122 Here we report that nystatin (NYT), an antifungal drug of the family of polyene macrolide antib

123 to recapitulate the exacerbating effects of antifungal drugs on allergic airway disease.

124 of the key intermediate of an orally active antifungal drug posaconazole (Noxafil).

125 The antifungal drug posaconazole that blocks sterol biosynth

126 1) were proven effective against Chagas, and antifungal drugs posaconazole and ravuconazole have ente

127 The use of antifungal drugs, primarily azoles and polyenes, has inc

128 nant resistance to the immunosuppressive and antifungal drug rapamycin (Rm).

129 hospitalization, and no patients experienced antifungal drug-related toxicity or IFD-associated morta

130 an also be advantageous and in fungi confers antifungal drug resistance and enables rapid adaptive ev

131 By tackling antifungal drug resistance as an evolutionary problem, t

132 We calculated candidemia incidence and antifungal drug resistance compared with prior surveilla

133 current knowledge of the mechanisms by which antifungal drug resistance evolves in experimental popul

134 e diagnosis, epidemiology, and mechanisms of antifungal drug resistance of pathogenic fungi.

135 We also identified the induction of an antifungal drug resistance response upon the treatment o

136 of Candida bloodstream infections (BSI) and antifungal drug resistance, population-based active labo

137 is due to relapse rather than reinfection or antifungal drug resistance.

138 erstand the molecular mechanisms that govern antifungal drug resistance.

139 that proper ergosterol levels are needed for antifungal drug resistance.

140 regulation, and uncover circuitry governing antifungal drug resistance.Cas5 is a transcriptional reg

141 lular, and molecular factors contributing to antifungal-drug resistance continues to accumulate.

142 Prolonged oral treatment of mice with antifungal drugs resulted in increased disease severity

143 ines why cells lacking H3K4 methylation have antifungal drug sensitivity.

144 tibility testing of 92 isolates against nine antifungal drugs showed a variety of results but high ac

145 A survey of azole antifungal drugs showed that CYP126A1 is inhibited stron

146 The PMAA resins bound cationic antifungal drugs such as miconazole and chlorhexidine di

147 ence of antagonism in combination with other antifungal drugs suggests that combination antifungal th

148 ioselective synthesis of the clinically used antifungal drug sulconazole.

149 Antifungal drug susceptibility can vary with molecular t

150 A rapid flow cytometric assay for in vitro antifungal drug susceptibility testing was developed by

151 anin synthesis, carbon assimilation pattern, antifungal drug susceptibility, colony morphology, growt

152 therapeutic strategy and identify Bdf1 as an antifungal drug target that can be selectively inhibited

153 uggest that CaEss1 might constitute a useful antifungal drug target, and that structural differences

154 h direction to uncover a new fungal specific antifungal drug target.

155 virulence is achieved, suggesting AHAS as an antifungal drug target.

156 , so fungal PS synthase is a potential novel antifungal drug target.

157 se genes were those previously identified as antifungal drug targets (i.e., FKS1, ERG1, and ERG11), v

158 These findings may expand the range of antifungal drug targets.

159 odel organisms and thus constitute candidate antifungal drug targets.

160 and identifies potential anticryptococcal or antifungal drug targets.

161 sm could lead to the identification of novel antifungal drug targets.

162 In general, of the eight antifungal drugs tested, voriconazole had the greatest i

163 g and were far more resistant to a number of antifungal drugs than commensal isolates from healthy in

164 Itraconazole is a safe and widely used antifungal drug that was recently found to possess poten

165 eveal constrained interactions with triazole antifungal drugs that are important for drug design and

166 ic activity of C. albicans CYP51 by clinical antifungal drugs that are used systemically (fluconazole

167 The echinocandins are relatively new antifungal drugs that represent, together with the older

168 iscovery of broad spectrum antiprotozoal and antifungal drugs that selectively block the capping of p

169 stems should facilitate rational screens for antifungal drugs that target cap formation in vivo.

170 egrity pathway would enhance the activity of antifungal drugs that target the cell wall.

171 on of conidia with various concentrations of antifungal drug, the percentage of residual glucose in t

172 of C. albicans to host-imposed stresses and antifungal drugs, the expression of key virulence factor

173 Current antifungal drug therapies are limited and suffer from to

174 of virulence, host-pathogen interactions and antifungal drug therapies in both the clinic and agricul

175 g pathogenesis, immunological effectors, and antifungal drug therapy for invasive pulmonary aspergill

176 may influence the management of patients on antifungal drug therapy.

177 logical activities of the most commonly used antifungal drug to promote DC maturation.

178 lts support the development of this class of antifungal drug to treat invasive candidiasis.

179 he development of drug combinations or novel antifungal drugs to address emerging drug resistance is

180 it was applied in a concise synthesis of the antifungal drug Tolciclate.

181 ce in a murine systemic infection model, and antifungal drug tolerance in C. lusitaniae.

182 vo ergosterol biosynthesis, brought about by antifungal drug treatment.

183 Amphotericin B (AmB) is the standard antifungal drug used on SSCC plates at a concentration o

184 We review the antifungal drugs used to treat cryptococcal meningitis w

185 Azoles are antifungal drugs used to treat fungal infections such as

186 39 NAIMI episodes, the MIC of the first-line antifungal drug was the most important predictor of ther

187 The affinity of the enzyme for antifungal drugs was characterized to investigate its po

188 e presence of a panel of chemotherapeutic or antifungal drugs, we found that some aneuploid strains g

189 Melanin and protease production and MICs of antifungal drugs were comparable for serial isolates.